News and Events

SITC 2019

An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs) Authors: Philip M. Arlen, MD; Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata,...

Immuno-Oncology Europe 2019

Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO, Precision Biologics, Inc, United States of America An allogeneic cancer vaccine developed from human tumors surgically resected had...

Novel Targets Of Neoantigens In Monoclonal Antibodies

Philip M. Arlen, M.D.Summary: Target is broadly expressed in multiple solid tumors.Exhibits both ADCC and CDC killing.Promising pre-clinical results with complete regression of tumor in animal models.GMP manufacturing completed.Pre-clinical testing showed...

2019 ASCO Annual Meeting

Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Session Title/Date/Time: Poster Session: Developmental Immunotherapy and Tumor Immunobiology, 6/1/2019, 8:00 AM-11:00 AM May 31 – June 4, 2019...

AACR Annual Meeting

Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019 - Atlanta, Georgia Session Category:   Clinical Research Session Title:  Immunomodulation by Chemotherapy and Targeted Agents Session Date and...

Precision Biologics

info@precision-biologics.com
301-500-8646
4814 Del Ray Avenue
Bethesda, MD 20814